Intellia Therapeutics (NTLA) presented its launch strategy for CRISPR-based therapy lonvo-z at a Morgan Stanley conference on September 14, outlining a targeted commercial footprint and reaffirming its cash position as the company awaits FDA action on the drug for hereditary angioedema (HAE).
CEO John Leonard and CFO Ed Dulac emphasized clinical durability data from Phase 1 through Phase 3 programs, noting that more than 100 patients have been treated across the development pipeline. "All patients eventually get to an HAE-free state," Dulac said. "Every single patient has gotten to HAE-free, and none have gone back to HAE." Durability extends beyond three years in Phase 3 patients and more than four years in the earliest-treated cohort.
In the Phase 3 program, lonvo-z demonstrated an 87% reduction in attack rate, with 62% of patients achieving attack-free status at the 28-week primary observation period. About 70% of Phase 3 patients were on long-term prophylaxis and 30% on on-demand therapy at baseline; roughly 20% had already achieved complete disease control prior to entering the trial.
The FDA has set a Prescription Drug User Fee Act (PDUFA) target date of March 10, 2025, for lonvo-z. The biotech announced BLA acceptance one week before the conference.
On the financial side, Intellia ended the second quarter with approximately $630 million in cash and a current ratio of 6.65, management projected the balance sheet would fund operations into 2028 without accounting for any lonvo-z revenue. The company carries a $300 million debt facility with OrbiMed, of which $75 million has been drawn and another $75 million is available upon lonvo-z approval, plus three additional $40 million tranches tied to sales milestones. Trailing twelve-month EBITDA was negative $414 million, and market capitalization stood at roughly $1.67 billion.
Commercially, Intellia plans to focus its launch on approximately 250 top prescribers who treat roughly half of U.S. HAE patients. Existing HAE therapies can exceed $700,000 annually, and management indicated pricing would fall in the range of two to five times that of current options, though no final price was disclosed.
Payer coverage for HAE currently splits roughly 70% commercial, 20% Medicare, and 10% Medicaid, and Intellia expects coverage to reach over 60% of the treatable population within six months of approval. A genetic screening consideration involves an HLA allele appearing in about 12% of European and Caucasian patients and 1–2% of African American patients.
Intellia retains ultimate decision-making authority and 75% of the economics in its Regeneron collaboration, which covers both lonvo-z for HAE and NTLA-2001 for TTR amyloidosis. Regeneron holds an option to co-promote in the U.S. on a minority basis, with no upfront payment, and must decide whether to exercise that right approximately two years before expected TTR approval.
Shares traded around $11.74 at the time of the conference, down roughly 8% over the prior week but up about 31% year-to-date. Analyst targets ranged from $8 to a high of $61, while InvestingPro's fair-value estimate came in at $13.83.
